Status:
COMPLETED
Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain
Lead Sponsor:
Abbott
Conditions:
Osteoarthritis, Knee
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve ...
Eligibility Criteria
Inclusion
- Moderate to severe pain attributed to knee osteoarthritis
Exclusion
- Significant comorbidity
- Significant pain states other than osteoarthritis
- Concomitant medications that might affect assessments
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00941746
Start Date
August 1 2009
End Date
January 1 2011
Last Update
June 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Ref # / Investigator 51568
Utrecht, Netherlands, 3584 CJ